Literature DB >> 8044122

Development of the Leeds Dependence Questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package.

D Raistrick1, J Bradshaw, G Tober, J Weiner, J Allison, C Healey.   

Abstract

The Leeds Dependence Questionnaire (LDQ) has been developed as part of a treatment evaluation package. The LDQ is a 10-item, self completion questionnaire designed to measure dependence upon a variety of substances; it has been shown to be understood by users of alcohol and opiates. The questionnaire was designed to be sensitive to change over time and to be sensitive through the range from mild to severe dependence; the follow-up data are insufficient to demonstrate change over time, but are encouraging. It is expected that both clinicians and researchers will find it useful to have a single measure relating to substance use, but not limited by specific substances. All items are scored 0-1-2-3; there are no normative data. The procedure for establishing content validity is described and estimates of concurrent, discriminant and convergent validities are reported; these validities are thought to be satisfactory. A principal components analysis produced a single factor accounting for 64% of the variance. Cronbach's alpha was 0.94. Test-retest reliability was found to be 0.95.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8044122     DOI: 10.1111/j.1360-0443.1994.tb03332.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  70 in total

Review 1.  Dependent behavior in patients with medication-overuse headache.

Authors:  Jong-Ling Fuh; Shuu-Jiun Wang
Journal:  Curr Pain Headache Rep       Date:  2012-02

2.  Public policy on alcohol in the United Kingdom: towards a safety net for the alcohol-dependent.

Authors:  Laura Williamson
Journal:  J Law Med       Date:  2009-12

3.  Effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT).

Authors: 
Journal:  BMJ       Date:  2005-09-10

4.  Risk Factors for Overdose in Treatment-Seeking Youth With Substance Use Disorders.

Authors:  Amy M Yule; Nicholas W Carrellas; Maura Fitzgerald; James W McKowen; Jessica E Nargiso; Brandon G Bergman; John F Kelly; Timothy E Wilens
Journal:  J Clin Psychiatry       Date:  2018 May/Jun       Impact factor: 4.384

5.  Is residential treatment effective for opioid use disorders? A longitudinal comparison of treatment outcomes among opioid dependent, opioid misusing, and non-opioid using emerging adults with substance use disorder.

Authors:  Zev Schuman-Olivier; M Claire Greene; Brandon G Bergman; John F Kelly
Journal:  Drug Alcohol Depend       Date:  2014-09-18       Impact factor: 4.492

6.  Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials.

Authors:  Katie Witkiewitz; Matthew R Pearson; Kevin A Hallgren; Stephen A Maisto; Corey R Roos; Megan Kirouac; Adam D Wilson; Kevin S Montes; Nick Heather
Journal:  Addiction       Date:  2017-06-26       Impact factor: 6.526

7.  Pain as a predictor of heavy drinking and any drinking lapses in the COMBINE study and the UK Alcohol Treatment Trial.

Authors:  Katie Witkiewitz; Kevin E Vowles; Elizabeth McCallion; Tessa Frohe; Megan Kirouac; Stephen A Maisto
Journal:  Addiction       Date:  2015-06-03       Impact factor: 6.526

8.  Psychometric validation of the Leeds Dependence Questionnaire (LDQ) in a young adult clinical sample.

Authors:  John F Kelly; Molly Magill; Valerie Slaymaker; Christopher Kahler
Journal:  Addict Behav       Date:  2009-12-03       Impact factor: 3.913

9.  Drug use disorder (DUD) questionnaire: scale development and validation.

Authors:  Michael Scherer; C Debra Furr-Holden; Robert B Voas
Journal:  Eval Rev       Date:  2013-05-27

10.  Drug-dependence behaviour and outcome of medication-overuse headache after treatment.

Authors:  Ilenia Corbelli; Stefano Caproni; Paolo Eusebi; Paola Sarchielli
Journal:  J Headache Pain       Date:  2012-10-18       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.